ADMA Biologics, Inc. (ADMA)

Market Cap	4.11B
Revenue (ttm)	382.81M
Net Income (ttm)	68.13M
Shares Out	236.39M
EPS (ttm)	0.28
PE Ratio	62.07
Forward PE	25.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,938,752
Open	17.16
Previous Close	17.90
Day's Range	17.08 - 17.96
52-Week Range	4.16 - 23.64
Beta	0.72
Analysts	Strong Buy
Price Target	21.25 (+22.13%)
Earnings Date	Nov 7, 2024

About ADMA

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other liste...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 624
• Stock Exchange: NASDAQ
• Ticker Symbol: ADMA
• Website: https://www.admabiologics.com

Financial Performance

In 2023, ADMA Biologics's revenue was $258.22 million, an increase of 67.59% compared to the previous year's $154.08 million. Losses were -$28.24 million, -57.15% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for ADMA stock is "Strong Buy." The 12-month stock price forecast is $21.25, which is an increase of 22.13% from the latest price.

Price Target

$21.25

(22.13% upside)

Analyst Consensus: Strong Buy